Dr. Graham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2015 Uppergate Drive NE
404
Atlanta, GA 30322Phone+1 404-785-3874Fax+1 404-785-1178- Is this information wrong?
Education & Training
- University of ColoradoFellowship, Pediatric Hematology/Oncology, 1999 - 2003
- University of ColoradoResidency, Pediatrics, 1996 - 1999
- University of North Carolina at Chapel Hill School of MedicineClass of 1996
- University of North Carolina at Chapel HillPh.D., 1990 - 1994
- Wake Forest UniversityB.S., Biology, With honors, 1983 - 1987
Certifications & Licensure
- GA State Medical License 2015 - 2025
- CO State Medical License 1998 - 2017
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Technology Transfer Office Bioscience Discovery Award University of Colorado, 2013
- Research Scholar Award American Cancer Society, 2009
- Damon Runyon-Novartis Clinical Investigator Award 2007
- Join now to see all
Clinical Trials
- Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Publications & Presentations
PubMed
- Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.James M Kelvin, Juhi Jain, Aashis Thapa, Min Qui, Lacey A Birnbaum, Samuel G Moore, Henry Zecca, Ryan J Summers, Jeffrey M Switchenko, Emma Costanza, Biaggio Uricoli, ...> ;Pharmaceutical Research. 2023 Sep 1
- TAM family kinases as therapeutic targets at the interface of cancer and immunity.Deborah DeRyckere, Justus M Huelse, H Shelton Earp, Douglas K Graham> ;Nature Reviews. Clinical Oncology. 2023 Nov 1
- 1 citationsIn vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.Yekaterina Galat, Yuchen Du, Mariana Perepitchka, Xiao-Nan Li, Irina V Balyasnikova, William T Tse, Svetlana Dambaeva, Sylvia Schneiderman, Philip M Iannaccone, Oren B...> ;Oncoimmunology. 2023 Jan 1
- Join now to see all
Journal Articles
- Efficacy of a dual Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaLee Sherick A, Zhang W, Menachof K, Hill A, Rinella S, Stashko M, Jordan C, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, and DK Graham, Oncotarget, 1/1/2015
- Epigenetic reprogramming to reverse chemoresistance in childhood acute lymphoblastic leukemiaNewton TP, Cummings CT, Graham DK, and KM Bernt, International Journal of Hematologic Oncology, 1/1/2014
- The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancerGraham DK, DeRyckere D, Davies KD, and HS Earp, Nat Rev Cancer, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemiaDeRyckere D, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
- Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancerCummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
- A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanomaEarp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
- Join now to see all
Lectures
- Targeted inhibition of MerTK as novel cancer therapyMadison, WI - 1/18/2015
- Transitioning MerTK Inhibitors Into the Clinic as Novel Cancer Therapy1/15/2015
- Development of dual Mer/FLT3 inhibitorsBoulder, CO - 1/12/2015
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- American Society of Pediatric Hematology/Oncology (ASPHO)Board Member - Vice President
Hospital Affiliations
- Children's Healthcare of AtlantaAtlanta, Georgia
External Links
- Aflac Cancer Centerhttp://www.aflaccancercenter.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: